Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Tumor lysis syndrome primary prevention

Introduction

Overview

Overview

Effective measures for the primary prevention of tumor lysis syndrome include allopurinol, rasburicase, and intravenous hydration.

Prevention

Prevention

Before initiating chemotherapy for cancer patients, especially lymphomas and leukemias, patients should receive the following:[1]

Patient population Treatment

Low risk

  • Adequate intravenous hydration to maintain a high urine output (> 2.5 L/day)
  • Alkalinization of urine is not recommended.[2]

Intermediate risk

  • Adults dosing: 200-400mg/m2/day in 1-3 divided doses; maximum dose is 800mg/day
  • Infants weighing less than 10kg: 3.3mg/kg every 8 hours

High risk

  • 0.2mg/kg for 5-7 days
  • A single dose of 3 mg may be used in high risk patients
  • Contraindicated in patients with glucose 6 phosphate dehydrogenase (G6PD) deficiency
References

References

  1. ↑ Jones, Gail L; Will, Andrew; Jackson, Graham H; Webb, Nicholas J A; Rule, Simon (2015). “Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology”. British Journal of Haematology. 169 (5): 661–671. doi:10.1111/bjh.13403. ISSN 0007-1048.
  2. ↑ Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM (1998). “Alkalinization and the tumor lysis syndrome”. Med Pediatr Oncol. 31 (1): 27–8. PMID 9607427.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]